Comparative study of lansoprazole and esomeprazole in first-line triple therapy for Helicobacter pylori infection-an open label randomized controlled trial

被引：0

作者：

Noda, Teruyo ^{[1
]}

Tamaki, Hiroyuki ^{[1
]}

Arasawa, Shuichi ^{[1
]}

Izuta, Masako ^{[1
]}

Kubo, Atsushi ^{[1
]}

Ogawa, Chikara ^{[1
]}

Matsunaka, Toshihiro ^{[1
]}

Shibatouge, Mitsushige ^{[1
]}

机构：

[1] Takamatsu Red Cross Hosp, Takamatsu, Kagawa, Japan

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2015年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1418

引用

页码：123 / 123

页数：1

共 50 条

[31] Metaanalysis: Moxifloxacin Triple Therapy for First-Line and Rescue Treatment of Helicobacter pylori Infection
Miehlke, Stephan
Ruecker, Gerta
Krasz, Susanne
Morgner, Andrea
Labenz, Joachim
[J]. GASTROENTEROLOGY, 2012, 142 (05) : S483 - S483
[32] Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy
Zhang, Wei
Chen, Qi
Liang, Xiao
Liu, Wenzhong
Xiao, Shudong
Graham, David Y.
Lu, Hong
[J]. GUT, 2015, 64 (11) : 1715 - 1720
[33] A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study
Ciccaglione, Antonio Francesco
Cellini, Luigina
Grossi, Laurino
Manzoli, Lamberto
Marzio, Leonardo
[J]. HELICOBACTER, 2015, 20 (05) : 390 - 396
[34] Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial
Lim, Hyun
Bang, Chang Seok
Shin, Woon Geon
Choi, Jae Ho
Soh, Jae Seung
Kang, Ho Suk
Yang, Young Joo
Hong, Ji Taek
Shin, Suk Pyo
Suk, Ki Tae
Lee, Jae Jun
Baik, Gwang Ho
Kim, Dong Joon
[J]. MEDICINE, 2018, 97 (46)
[35] Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial
Bago, Josip
Pevec, Branko
Tomic, Monika
Marusic, Marinko
Bakula, Vinko
Bago, Petra
[J]. WIENER KLINISCHE WOCHENSCHRIFT, 2009, 121 (1-2) : 47 - 52
[36] Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial
Zhang, Xiao-Dong
Zhang, Da-Ya
Chen, Run-Xiang
Chen, Shi-Ju
Chen, Chen
Zeng, Fan
Huang, Shi-Mei
Li, Da
Bai, Fei-Hu
[J]. BMC GASTROENTEROLOGY, 2023, 23 (01)
[37] Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial
Xiao-Dong Zhang
Da-Ya Zhang
Run-Xiang Chen
Shi-Ju Chen
Chen Chen
Fan Zeng
Shi-Mei Huang
Da Li
Fei-Hu Bai
[J]. BMC Gastroenterology, 23
[38] Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
Liou, Jyh-Ming
Fang, Yu-Jen
Chen, Chieh-Chang
Bair, Ming-Jong
Chang, Chi-Yang
Lee, Yi-Chia
Chen, Mei-Jyh
Chen, Chien-Chuan
Tseng, Cheng-Hao
Hsu, Yao-Chun
Lee, Ji-Yuh
Yang, Tsung-Hua
Luo, Jiing-Chyuan
Chang, Chun-Chao
Chen, Chi-Yi
Chen, Po-Yueh
Shun, Chia-Tung
Hsu, Wen-Feng
Hu, Wen-Hao
Chen, Yen-Nien
Sheu, Bor-Shyang
Lin, Jaw-Town
Wu, Jeng-Yih
El-Omar, Emad M.
Wu, Ming-Shiang
[J]. LANCET, 2016, 388 (10058): : 2355 - 2365
[39] BISMUTH, ESOMEPRAZOLE, METRONIDAZOLE AND AMOXICILLIN OR TETRACYCLINE AS A FIRST-LINE REGIMEN FOR HELICOBACTER PYLORI ERADICATION: A RANDOMISED CONTROLLED TRIAL
Tian, Xueli
Suo, Baojun
Zhang, Hua
Lu, Haoping
Li, Cailing
Zhang, Yuxin
Ren, Xinlu
Yao, Xingyu
Zhou, Liya
Song, Zhiqiang
[J]. GASTROENTEROLOGY, 2023, 164 (06) : S47 - S47
[40] Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial
Sanjeev Kumar Jha
Manish K. Mishra
Kuldeep Saharawat
Praveen Jha
Shubham Purkayastha
Ravish Ranjan
[J]. Indian Journal of Gastroenterology, 2019, 38 : 325 - 331

← 1 2 3 4 5 →